Sanofi profit lifted by early vaccine sales, dupixent growth

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent. Earnings per share excluding some items reached €2.86 ($3.10) in the third quarter, Sanofi said Friday. That exceeded analysts’ estimates, helped…







